Cover Image
市場調查報告書

OpportunityAnalyzer:登革熱疫苗的市場機會分析及市場預測

OpportunityAnalyzer: Dengue Vaccines - Opportunity Analysis and Forecasts to 2020 - Event-Driven Update

出版商 GlobalData 商品編碼 308244
出版日期 內容資訊 英文 211 Pages
訂單完成後即時交付
價格
Back to Top
OpportunityAnalyzer:登革熱疫苗的市場機會分析及市場預測 OpportunityAnalyzer: Dengue Vaccines - Opportunity Analysis and Forecasts to 2020 - Event-Driven Update
出版日期: 2014年09月30日 內容資訊: 英文 211 Pages
簡介

登革熱是單鏈黃病毒的登革熱病毒(DENV)所引發的發熱性疾病、主要媒介是埃及斑蚊(Aedes aegypti)。每年1億人以上被受感染、是全球最廣泛流行的節肢動物媒介性病毒。

本報告書為、登革熱疫苗市場的調查、登革熱的概要、發病件數和人口及地理的介紹、主要國家(巴西、印度、墨西哥、新加坡、泰國)的監視、預防、控制對策的現況、尚未被滿足的需求、疫苗開發事業者的R&D策略、主要開發平台藥的介紹、市場成長的影響因素分析、市場規模的推移和預測等彙整。

機會分析及市場預測

第1章 目次

第2章 介紹

第3章 疾病概要

  • 病因和病態生理
  • 症狀
  • 預測

第4章 免疫學

  • 疾病的背景
  • 風險因素和併存症
  • 全球的趨勢
    • 發病率和地理的分佈
    • 登革熱的週期性、季節性模式
    • 登革熱的血清型
  • 預測方法
  • 登革熱的免疫學預測
    • 登革熱已確認檢查完成的報告件數
    • 登革熱已確認檢查完成的報告件數之男女比
    • 登革熱已確認檢查完成件數的年齡分佈
    • 登革熱已確認檢查完成的報告件數的年齡調整罹患率
  • 討論
    • 免疫學的預測考察
    • 分析的界線
    • 分析的強勢

第5章 目前的監視、預防、控制對策

  • 概要
  • 巴西
    • 監視和診斷
    • 媒介控制
    • 免疫化推薦和基礎設備
  • 印度
    • 監視和診斷
    • 媒介控制
    • 免疫化推薦和基礎設備
  • 墨西哥
    • 監視和診斷
    • 媒介控制
    • 免疫化推薦和基礎設備
  • 新加坡
    • 監視和診斷
    • 媒介控制
    • 免疫化推薦和基礎設備
  • 泰國
    • 監視和診斷
    • 媒介控制
    • 免疫化推薦和基礎設備

第6章 尚未被滿足的評價、市場機會分析

  • 概要
  • 尚未被滿足的分析
    • 安全且有效果的疫苗
    • 登革熱免疫的相關理解認知
    • 可信賴的免疫學保護相關因子
    • 國家固有的免疫化計畫之準備體制
    • 媒介控制和監視基礎設備的升級
    • 改良型診斷工具
    • 高品質動物模式
  • 市場機會分析
    • 單次給藥的登革熱疫苗的開發
    • 登革熱免疫的T細胞角色之解明
    • 創新的臨床試驗設計之疫苗開發的合理化
    • 多方面的登革熱防止計畫統合疫苗並與公共醫療相關人員合作
    • 國家固有的疫苗開始策略的確立
    • 宣傳疫苗有效性的診斷之活用

第7章 R&D策略

  • 概要
  • 疫苗開發的技術對策
    • 疫苗抗原的選定
    • 4價疫苗的配置
  • 聯盟、收購、許可契約
  • 臨床試驗設計
    • 現在的臨床試驗設計
    • 代表的患者人口之臨床試驗的投入
    • 預防效果的證明
    • 登革熱的人類感染模式

第8章 開發平台分析

  • 概要
  • 臨床開發中的減毒活疫苗
    • CYD-TDV
    • DENVax
    • TV-003
  • 其他臨床開發中的疫苗
    • TDENV-PIV
    • DEN-80E
  • 前臨床開發階段的疫苗

第9章 開發平台評價分析

  • 主要開發平台疫苗的臨床性標記
  • 主要開發平台疫苗的商業性標記
  • 競爭分析
  • 首屈5年間預測
    • 巴西
    • 印度
    • 墨西哥
    • 新加坡
    • 泰國

第10章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC006EPOA

Dengue is a febrile illness caused by the dengue virus (DENV), a single-stranded flavivirus most commonly transmitted by the Aedes aegypti (A. aegypti) mosquito. Thought to be responsible for upwards of 100 million infections each year, DENV is the most prevalent arthropod-borne virus in the world. Individuals infected with DENV can present with a wide spectrum of symptoms, including fevers, retro-orbital pain, severe headache, muscle and joint pain, and rash. The severity of dengue fever ranges from asymptomatic cases, to classic dengue fever, and to dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS) that have a mortality rate of 5%-15%. Because there are no marketed dengue-specific vaccines or therapeutics, current treatment strategies are limited to supportive care for those already infected with the virus, and vector control to reduce DENV transmission. The near-universal failure of these measures to curtain transmission and reduce disease burden across the global marketplace - which for the purposes of this report is comprised of Brazil, India, Mexico, Singapore, and Thailand - has further enhanced the need for safe and effective vaccines. GlobalData expects the launch of the first dengue vaccines, led by Sanofi Pasteur's CYD-TDV and Takeda's TAK-003, to revolutionize the treatment and prevention paradigm.

Highlights

Key Questions Answered

  • Based on interviews with key opinion leaders (KOLs), GlobalData has identified the major unmet needs in the dengue vaccine marketplace. Will the leading pipeline agents fulfil these unmet needs during the forecast period (2015-2020)?
  • What research and development (R&D) strategies will companies leverage to compete in the future dengue vaccine marketplace?
  • Which patient population(s) are most likely to be targeted for routine and catch-up immunization?
  • What clinical and environmental factors are likely to influence dengue vaccine uptake in Brazil, India, Mexico, Singapore, and Thailand? Which of these markets will experience the strongest growth from 2015-2020?

Key Findings

  • GlobalData projects the dengue vaccine market in Brazil, India, Mexico, Singapore, and Thailand to grow from $50.8m in 2015 to $486.2m in 2020, at a compound annual growth rate (CAGR) of 57.1%. This rapid growth will be driven by the expected incorporation of newly-launched dengue vaccines into routine and catch-up immunization programs.
  • KOLs interviewed by GlobalData expect the live-attenuated dengue vaccines - led by Sanofi Pasteur's CYD-TDV and Takeda's TAK-003 - to dominate the marketplace for the duration of the forecast period.
  • GlobalData anticipates that firms will increasingly turn to innovative R&D strategies, in particular the exploration of alternative approaches to early-stage clinical trial design - such as the dengue human infection model (DHIM) - in order to increase developmental efficiency, minimize upfront risk, and gain a competitive advantage over rivals.
  • Domestically-supplied vaccines, most notably Butantan Institute's TV-003 in Brazil and Panacea Biotech's/Biological E's TV-003 in India, are projected to limit market growth due to their low price relative to vaccines produced by privately-held foreign companies.

Scope

  • Overview of dengue virus (DENV), including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current disease surveillance and prevention measures.
  • Topline dengue vaccine market revenue from 2015-2020. Annual cost of therapy (ACOT) and major pipeline vaccine sales in this forecast period are included.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strategies, and clinical trial design for the dengue vaccine market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline vaccines. An interactive clinical and commercial analyzer tool is available.
  • Analysis of the current and future market competition in the global dengue vaccine market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global dengue vaccine market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the dengue vaccine market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms
  • 3.3. Prognosis

4. Epidemiology

  • 4.1. Disease Background
  • 4.2. Risk Factors and Comorbidities
  • 4.3. Global Trends
    • 4.3.1. Incidence and Geographic Distribution
    • 4.3.2. Dengue Periodic and Seasonal Patterns
    • 4.3.3. Dengue Serotypes
  • 4.4. Forecast Methodology
    • 4.4.1. Sources Used
    • 4.4.2. Sources Not Used
    • 4.4.3. Forecast Assumptions and Methods
  • 4.5. Epidemiological Forecast for Dengue (2013-2023)
    • 4.5.1. Reported Laboratory-Confirmed Dengue Cases
    • 4.5.2. Sex-Specific Distribution of Reported Laboratory-Confirmed Dengue Cases
    • 4.5.3. Age-Specific Distribution of Reported Laboratory-Confirmed Dengue Cases
    • 4.5.4. Age-Standardized Incidence of Reported Laboratory-Confirmed Dengue
  • 4.6. Discussion
    • 4.6.1. Epidemiological Forecast Insight
    • 4.6.2. Limitations of the Analysis
    • 4.6.3. Strengths of the Analysis

5. Current Surveillance, Prevention, and Control Measures

  • 5.1. Overview
  • 5.2. Brazil
    • 5.2.1. Surveillance and Diagnosis
    • 5.2.2. Vector Control
    • 5.2.3. Immunization Recommendations and Infrastructure
  • 5.3. India
    • 5.3.1. Surveillance and Diagnosis
    • 5.3.2. Vector Control
    • 5.3.3. Immunization Recommendations and Infrastructure
  • 5.4. Mexico
    • 5.4.1. Surveillance and Diagnosis
    • 5.4.2. Vector Control
    • 5.4.3. Immunization Recommendations and Infrastructure
  • 5.5. Singapore
    • 5.5.1. Surveillance and Diagnosis
    • 5.5.2. Vector Control
    • 5.5.3. Immunization Recommendations and Infrastructure
  • 5.6. Thailand
    • 5.6.1. Surveillance and Diagnosis
    • 5.6.2. Vector Control
    • 5.6.3. Immunization Recommendations and Infrastructure

6. Unmet Needs Assessment and Opportunity Analysis

  • 6.1. Overview
  • 6.2. Unmet Needs Analysis
    • 6.2.1. Unmet Need: Safe and Efficacious Vaccines
    • 6.2.2. Unmet Need: An Improved Understanding of Dengue Immunity
    • 6.2.3. Unmet Need: Reliable Immunological Correlates of Protection
    • 6.2.4. Unmet Need: Country-Specific Immunization Program Preparedness
    • 6.2.5. Unmet Need: Upgraded Vector Control and Surveillance Infrastructures
    • 6.2.6. Unmet Need: Improved Diagnostic Tools
    • 6.2.7. Unmet Need: High-Quality Animal Models
  • 6.3. Opportunity Analysis
    • 6.3.1. Opportunity: Develop a Single-Dose Dengue Vaccine
    • 6.3.2. Opportunity: Further Elucidate the Role(s) of T Cells in Dengue Immunity
    • 6.3.3. Opportunity: Streamline Vaccine Development with Innovative Clinical Trial Design
    • 6.3.4. Opportunity: Partner with Public Health Stakeholders to Integrate Vaccines into Multifaceted Dengue Prevention Programs
    • 6.3.5. Opportunity: Establish Country-Specific Vaccine Launch Strategies
    • 6.3.6. Opportunity: Leverage Diagnostics to Demonstrate Vaccine Effectiveness Post-Licensure

7. Research and Development Strategies

  • 7.1. Overview
  • 7.2. Technological Approaches to Vaccine Development
    • 7.2.1. Vaccine Antigen Selection
    • 7.2.2. Tetravalent Vaccine Construction
  • 7.3. Partnerships, Acquisitions, and Licensing Agreements
  • 7.4. Clinical Trial Design
    • 7.4.1. Current Clinical Trial Design
    • 7.4.2. Inclusion of Representative Patient Populations in Clinical Trials
    • 7.4.3. Demonstration of Protective Efficacy
    • 7.4.4. Dengue Human Infection Model

8. Pipeline Assessment

  • 8.1. Overview
  • 8.2. Live-Attenuated Vaccines in Clinical Development
    • 8.2.1. CYD-TDV
    • 8.2.2. TAK-003
    • 8.2.3. TV-003
  • 8.3. Other Vaccines in Clinical Development
    • 8.3.1. TDENV-PIV
    • 8.3.2. DEN-80E
  • 8.4. Vaccines in Preclinical Development

9. Pipeline Valuation Analysis

  • 9.1. Clinical Benchmarking of Key Pipeline Vaccines
  • 9.2. Commercial Benchmarking of Key Pipeline Vaccines
  • 9.3. Competitive Assessment
  • 9.4. Top-Line Five-Year Forecast
    • 9.4.1. Brazil
    • 9.4.2. India
    • 9.4.3. Mexico
    • 9.4.4. Singapore
    • 9.4.5. Thailand

10. Appendix

  • 10.1. Bibliography
  • 10.2. Abbreviations
  • 10.3. Methodology
  • 10.4. Forecasting Methodology
    • 10.4.1. Vaccinated Patients
    • 10.4.2. Vaccination Coverage Rates
    • 10.4.3. Vaccines Included in Each Class
    • 10.4.4. Vaccine Launch Dates
    • 10.4.5. General Pricing Assumptions
    • 10.4.6. Individual Vaccine Assumptions
    • 10.4.7. Pricing of Pipeline Vaccines
  • 10.5. Physicians and Specialists Included in this Study
  • 10.6. About the Authors
    • 10.6.1. Analyst
    • 10.6.2. Epidemiologist
    • 10.6.3. Therapy Area Director
    • 10.6.4. Global Head of Healthcare
  • 10.7. About GlobalData
  • 10.8. Disclaimer

List of Tables

  • Table 1: Symptoms and WHO Case Definitions of Dengue
  • Table 2: Risk Factors for DENV Transmission and Severe Dengue (DHF and DSS)
  • Table 3: Periodicity and Seasonality of Dengue Fever in the 5MM, 2003-2013
  • Table 4: 5MM, Circulating DENV Serotypes and Predominant Serotype, 2003-2013
  • Table 5: 5MM, Sources of Reported Laboratory-Confirmed Dengue Fever Data
  • Table 6: 5MM, Reported Laboratory-Confirmed Dengue Cases, N (Col %), Men and Women, All Ages, Selected Years, 2009-2023
  • Table 7: 5MM, Sex-Specific Distribution of Reported Laboratory-Confirmed Dengue Cases, All Ages, Annual Average, 2009-2013
  • Table 8: 5MM, Age-Specific Distribution of Reported Laboratory-Confirmed Dengue Cases, All Ages, Annual Average, 2009-2013
  • Table 9: Routine Immunization Recommendations in Brazil, 2014
  • Table 10: Routine Immunization Recommendations in India, 2014
  • Table 11: Routine Immunization Recommendations in Mexico, 2014
  • Table 12: Routine Immunization Recommendations in Singapore, 2014
  • Table 13: Routine Immunization Recommendations in Thailand, 2014
  • Table 14: Unmet Need and Opportunity in Dengue Vaccines
  • Table 15: Acquisitions and Licensing Agreements in the Dengue Vaccine Market, 2014
  • Table 16: Design of Selected Dengue Vaccine Clinical Trials
  • Table 17: Dengue Vaccines - Clinical Development Pipeline, 2014
  • Table 18: Comparison of Dengue Vaccine Classes in Clinical Development, 2014
  • Table 19: Product Profile - CYD-TDV
  • Table 20: Phase III Efficacy Profile - CYD-TDV
  • Table 21: Exploratory Intent-to-Treat Efficacy Analyses - CYD-TDV
  • Table 22: Phase IIb Efficacy Profile - CYD-TDV
  • Table 23: Safety Profile - CYD-TDV
  • Table 24: CYD-TDV SWOT Analysis, 2014
  • Table 25: Product Profile - TAK-003
  • Table 26: Efficacy Profile - TAK-003
  • Table 27: Safety Profile - TAK-003
  • Table 28: TAK-003 SWOT Analysis, 2014
  • Table 29: Product Profile - TV-003
  • Table 30: Efficacy Profile - TV-003
  • Table 31: Safety Profile - TV-003
  • Table 32: TV-003 SWOT Analysis, 2014
  • Table 33: Product Profile - TDENV-PIV
  • Table 34: TDENV-PIV SWOT Analysis, 2014
  • Table 35: Product Profile - DEN-80E
  • Table 36: Efficacy Profile - DEN-80E
  • Table 37: DEN-80E SWOT Analysis, 2014
  • Table 38: Dengue Vaccines - Innovative Vaccines in Preclinical Development, 2014
  • Table 39: Clinical Benchmarking of Key Pipeline Vaccines
  • Table 40: Commercial Benchmarking of Key Pipeline Vaccines
  • Table 41: Top-Line Sales Forecast ($m) for Dengue Vaccines, 2015-2020
  • Table 42: Key Events Impacting Sales for Dengue Vaccines, 2015-2020
  • Table 43: Dengue Vaccines Market - Drivers and Barriers, 2015-2020
  • Table 44: Key Launch Dates

List of Figures

  • Figure 1: DENV Structure and Genome
  • Figure 2: Laboratory Methods for Dengue Diagnosis
  • Figure 3: 5MM, Incidence Rate (Cases per 100,000 Population) of Reported Laboratory-Confirmed Dengue Cases (Including Classic Dengue Fever and DHF), Men and Women, All Ages, 2003-2013
  • Figure 4: 5MM, Reported Laboratory-Confirmed Dengue Cases, Men and Women, All Ages, 2014-2023
  • Figure 5: 5MM, Sex-Specific Distribution of Reported Laboratory-Confirmed Dengue Cases, All Ages, Annual Average, 2009-2013
  • Figure 6: 5MM, Age-Specific Distribution of Reported Laboratory-Confirmed Dengue Cases, Men and Women, Annual Average, 2009-2013
  • Figure 7: 5MM, Age-Standardized Incidence of Reported Laboratory-Confirmed Dengue Cases, All Ages, Annual Average, 2009-2013
  • Figure 8: Competitive Assessment of Pipeline Dengue Vaccines, 2015-2020
  • Figure 9: Global Dengue Vaccine Uptake, by Routine or Catch-up Immunization, 2015-2020
  • Figure 10: Global Sales for Pipeline Dengue Vaccines by Country, 2015-2020
  • Figure 11: Brazil Dengue Vaccine Uptake, by Routine or Catch-up Immunization, 2015-2020
  • Figure 12: India Dengue Vaccine Uptake, by Routine or Catch-up Immunization, 2015-2020
  • Figure 13: Mexico Dengue Vaccine Uptake, by Routine or Catch-up Immunization, 2015-2020
  • Figure 14: Singapore Dengue Vaccine Uptake, by Routine or Catch-up Immunization, 2015-2020
  • Figure 15: Thailand Dengue Vaccine Uptake, by Routine or Catch-up Immunization, 2015-2020
Back to Top